Page 305 of 1,034: studies 3,041 to 3,050 of 10,336, newest first. Back to the depression overview
2015 S. Verma
Background and Objective: The objective was to evaluate clinical trial data on the use of ketamine in treating treatment-resistant depression (TRD). Materials and Methods: PubMed search (November 2012) was initiated using the keywords: Ketamine, resistant depression. Inclusion criterion included: English language publications describing clinical trial reports on humans with TRD. Results: A...
Neural Plasticity 2015 Annie J. Xu, Mark J. Niciu, Nancy B. Lundin et al. 27 citations
Ketamine and lithium both inhibit glycogen synthase kinase 3. In addition, lithium and ketamine have synergistic antidepressant-like effects at individually subeffective doses in rodents. We hypothesized that ketamine's antidepressant effects would be improved by therapeutic doses of lithium versus valproate and that serum lithium levels would positively correlate with ketamine's antidepressant...
Frontiers in Psychiatry 2015 Charles F Zorumski, Peter Nagele, Steven Mennerick et al.
Major depressive disorder (MDD) remains a huge personal and societal encumbrance. Particularly burdensome is a virulent subtype of MDD, treatment resistant major depression (TMRD), which afflicts 15-30% of MDD patients. There has been recent interest in N-methyl-d-aspartate receptors (NMDARs) as targets for treatment of MDD and perhaps TMRD. To date, most pre-clinical and clinical studies have...
Depression Research and Treatment 2015 Basant Pradhan, Tapan Parikh, Ramkrishna Makani et al. 24 citations
Depression affects about 121 million people worldwide and prevalence of major depressive disorder (MDD) in US adults is 6.4%. Treatment resistant depression (TRD) accounts for approximately 12–20% of all depression patients and costs $29–$48 billion annually. Ketamine and repetitive transcranial magnetic stimulation (rTMS) have useful roles in TRD, but their utility in long term is unknown. As...
Elife December 12, 2014 Thu N Huynh, Eric Klann 1 citation
Genetically modified mice shed new light on how ketamine can target NMDA receptors in the brain to reduce the symptoms of depression.
Behaviour Research and Therapy December 1, 2014 Catherine Crane, Rebecca S. Crane, Catrin Eames et al.
Few empirical studies have explored the associations between formal and informal mindfulness home practice and outcome in Mindfulness-based Cognitive Therapy (MBCT). In this study ninety-nine participants randomised to MBCT in a multi-centre randomised controlled trial completed self-reported ratings of home practice over 7 treatment weeks. Recurrence of Major Depression was assessed...
Bipolar Disorders November 14, 2014 Dawn F. Ionescu, David A. Luckenbaugh, Mark J. Niciu et al. 109 citations
OBJECTIVE: Patents with anxious bipolar disorder have worse clinical outcomes and are harder to treat with traditional medication regimens compared to those with non-anxious bipolar disorder. Ketamine has been shown to rapidly and robustly decrease symptoms of depression in depressed patients with bipolar disorder. We sought to determine whether baseline anxiety status reduced ketamine's...
Medical Care November 13, 2014 J. Greg Serpa, Stephanie L. Taylor, Kirsten Tillisch 169 citations
INTRODUCTION: Anxiety, depression, and pain are major problems among veterans, despite the availability of standard medical options within the Veterans Health Administration. Complementary and alternative approaches for these symptoms have been shown to be appealing to veterans. One such complementary and alternative approach is mindfulness-based stress reduction (MBSR), a brief course that...
Current Neuropharmacology November 12, 2014 Gianluca Serafini, Robert H Howland, Fabiana Rovedi et al. 238 citations
BACKGROUND: At least 10-20% of the patients suffering from depression meet criteria for treatment-resistant depression (TRD). In the last decades, an important role of glutamate in mood modulation has been hypothesized and ketamine, a non noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptors, has been demonstrated to be effective in both MDD and TRD. However, concerns emerged...
Behavioural Neurology November 12, 2014 Adam W. Levin, Emily J. Hadgkiss, T. Weiland et al.
Objectives. To explore the association between meditation and health related quality of life (HRQOL), depression, fatigue, disability level, relapse rates, and disease activity in a large international sample of people with multiple sclerosis (MS). Methods. Participants were invited to take part in an online survey and answer questions relating to HRQOL, depression, fatigue, disability, relapse...